ArticleCancer medicine2026
Tertiary Lymphoid Structures as Predictors of Recurrence in Colorectal Cancer: Development and Validation of a Machine Learning-Based Scoring Model.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTertiary lymphoid structures (TLS) are prognostic immune aggregates in the tumor microenvironment, but the value of location-specific TLS features for predicting colorectal cancer (CRC) recurrence remains unclear. This study developed and internally validated a machine-learning (ML) model integrating TLS features for recurrence prediction in stage II-III CRC.
methodsWe retrospectively included 224 patients with stage II-III CRC after curative resection and split them into training (n = 156) and held-out internal validation (n = 68) cohorts. TLS at intratumoral, invasive-front, and peritumoral sites were semi-quantitatively scored by two blinded pathologists. LASSO selected predictors from 39 candidate variables. Five ML algorithms were trained with stratified cross-validation, predefined tuning, and training-only preprocessing. Performance was evaluated using discrimination, calibration, decision-curve/clinical-impact analyses, reclassification indices, SHAP interpretation, and Kaplan-Meier risk stratification.
resultsRecurrence occurred in 89 patients (39.7%). LASSO retained peritumoral TLS score, invasive-front TLS score, and preoperative CEA. TLS scoring showed high interobserver agreement (weighted kappa: 0.82-0.86). LightGBM provided the most balanced performance, with AUCs of 0.872 (95% CI: 0.814-0.923) in training and 0.718 (95% CI: 0.572-0.839) in internal validation. SHAP ranked invasive-front TLS score as the most influential predictor. The Youden cutoff (0.5017) separated high- and low-risk groups with significantly different disease-free survival (log-rank p < 0.0001; hazard ratio = 5.132, 95% CI: 3.263-8.073). In exploratory comparison, validation AUCs were 0.727 for TLS-only, 0.542 for clinical-only, and 0.737 for combined models.
conclusionsA TLS-based ML model showed moderate internal validation performance for CRC recurrence prediction. Location-specific TLS features may support postoperative risk stratification, but external multicenter and molecularly integrated validation is required before clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.